Recent EU Life Sciences Regulatory Changes – What You Need to Know
Friday, February 06, 2026
At the beginning of December 2025, the EU institutions achieved a significant political agreement on the EU Pharma Package, marking a pivotal revision to the pharmaceutical legislation. This overhaul aims to enhance the affordability, accessibility, and availability of medicines across the European Union. Key reforms focus on adjusting regulatory data protection and market protection periods for innovative medicinal products. The baseline now stands at eight years of data protection plus one year of market protection, with potential extensions to up to 11 years of market protection if specific conditions are fulfilled. These conditions introduce added complexity, as companies must demonstrate compliance with precise criteria, creating uncertainty about which products will qualify for extended protections.
Further, the agreement imposes obligations on companies to ensure authorised medicines are supplied in sufficient quantities across all EU member states to meet patient needs. Member states gain the authority to mandate supply, and non-compliance could result in the loss of market protection in the offending country. This provision underscores the EU's commitment to equitable access but raises questions about enforcement mechanisms and practical implementation by national authorities. While this political milestone is crucial, the final legislative text, expected soon, will clarify operational details. Stakeholders await this to fully assess impacts on R&D investments and commercial strategies.
In parallel, the EU Commission proposed targeted simplifications to the Medical Devices Regulation (MDR) and In Vitro Diagnostic Devices Regulation (IVDR). Criticised for excessive administrative burdens, delays, and complexity since their rollout, these reforms seek to streamline conformity assessments, adopt a more risk-based approach, and cut costs for manufacturers and notified bodies. Proposals include simplified procedures, practical improvements in relationships with notified bodies, and shorter reporting timelines. Specific adjustments target breakthrough and orphan devices, alongside tweaks to the in-house hospital exemption. Now entering parliamentary and council review, these changes may face amendments, potentially delaying implementation by a couple of years.
Simultaneously, a comprehensive EU Biotech Act was unveiled to elevate Europe's position as a biotech and biomanufacturing hub. It proposes streamlined regulations, expanded funding access, and innovation incentives to accelerate product development and market entry. Extending beyond health biotech, it reforms the Clinical Trials Regulation for faster approvals, and addresses overlapping rules for food safety, substances of human origin, and GMOs. Legislative discussions will likely modify the text, with a second Biotech Act anticipated later in 2026. These initiatives reflect broader EU trends: modernising pathways to foster competitiveness while prioritising safety through risk-proportionate measures.
For the life sciences industry, these developments demand proactive engagement in legislative processes to shape outcomes that balance innovation speed with patient access. Companies must prepare for evolving compliance landscapes, reassess IP strategies under new protections, and optimise supply chains for pan-EU availability. Morgan Lewis highlights its expanded regulatory team in Brussels, London, and Munich to guide firms through these shifts. A forthcoming webinar will dissect the Pharma Package details. Overall, this regulatory wave positions Europe for enhanced biopharma leadership, urging executives to monitor closely and adapt strategies accordingly. Implications span R&D prioritisation, manufacturing scalability, and market expansion plans across biotech, pharma, and medtech sectors.
Industry voices emphasise the need for balanced reforms that remove barriers without compromising rigorous standards. The Pharma Package's supply mandates, for instance, could reshape distribution models, prompting investments in resilient supply chains. Similarly, MDR simplifications may alleviate Notified Body bottlenecks, enabling faster device launches critical for integrated pharma-device solutions. The Biotech Act's funding boosts could fuel venture inflows, mirroring recent successes like Belgian firm Agomab's IPO, though focused on EU competitiveness. As these proposals advance, cross-sector collaboration will be key to realising Europe's ambition as a global life sciences powerhouse.
